Structure via PubChem · Public domain (PubChem)
oxaprozin
Sign in to saveAlso known as Daypro®, WY-21743, Deflam, Walix, Danoprox, Oxaprozinum, Oxaprozina
Oxaprozin, also known as oxaprozinum, is a nonsteroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative. Safety and efficacy has been established in children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.
Chemical data
- Formula
- C18H15NO3
- Molecular weight
- 293.3 g/mol
- IUPAC name
- 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid
- SMILES
- C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3
- InChIKey
- OFPXSFXSNFPTHF-UHFFFAOYSA-N
- XLogP
- 4.2
- Polar surface area
- 63.3 Ų
- H-bond donors
- 1
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Research
195 papers- Oxaprozin.2012
- Oxaprozin.2006
- Oxaprozin: a new NSAID.Orthopaedic review · 1992
- Clinical pharmacokinetics of oxaprozin.Clinical pharmacokinetics · 1998
- Oxaprozin. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.Drugs · 1986
via PubMed
Wikidata facts
- Mass
- 293.105
Show 5 more facts
- chemical formula
- C₁₈H₁₅NO₃
- canonical SMILES
- C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3
- World Health Organisation international non-proprietary name
- oxaprozin
- defined daily dose
- 0.9
- Commons category
- Oxaprozin
Sources (6)
via Wikidata · CC0
~4 min read
Article
7 sectionsContents
- Medical uses
- Adverse effects
- History
- Society and culture
- FDA approval
- Recalls
- References
Oxaprozin, also known as oxaprozinum, is a nonsteroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative. Safety and efficacy has been established in children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.
It was patented in 1967 and approved for medical use in 1983.